Compare Moderna, Inc. (MRNA) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs VICI Properties Inc — how do they compare? Moderna, Inc. trades at $59.72 (market cap $23.60B), while VICI Properties Inc trades at $26.7 (market cap $29.55B). The key difference: VICI Properties Inc is the larger of the two by market cap, and VICI Properties Inc pays a 6.71% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | VICI | |
|---|---|---|
Market Cap | $23.60B | $29.55B |
Sector | Health | Real Estate |
52-Week High | $81.80 | $33.93 |
52-Week Low | $22.36 | $25.94 |
Enterprise Value | $19.70B | $46.77B |
Dividend Yield | — | 6.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
VICI Properties trades at $26.83, down slightly (-0.15%) on the day. The stock shows strong fundamentals with a P/E of 9.19, net income margin of 76.83%, and consistent earnings beats in recent quarters. Technical indicators are mixed with an overall bullish signal but bearish moving averages. Recent news highlights institutional activity with CalPERS reducing its stake while Aviance Capital Partners initiated a new position.
VICI offers a compelling investment case with attractive valuation metrics, robust profitability, and a 6.62% dividend yield. However, risks include tenant concentration with Caesars/MGM accounting for 70% of rent and potential lease uncertainties from recent buyout discussions. Analyst consensus remains strongly bullish with a $29.00 price target suggesting 8% upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
